The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | CRICKET and CAVE: cetuximab for the treatment of mCRC
Erika Martinelli, MD, PhD, University of Campania Luigi Vanvitelli, Caserta, Italy, talks on findings from the CRICKET (NCT02296203) and CAVE (NCT04561336) trials. In the CRICKET trial, patients with KRAS, NRAS and BRAF wild-type, irinotecan-resistant metastatic colorectal cancer (mCRC) who were progressing after an initial response to a first-line cetuximab-containing therapy, received a rechallenge third-line treatment with cetuximab plus irinotecan. In the CAVE trial, the safety and efficacy of cetuximab plus avelumab, in patients with RAS wild-type (WT) mCRC treated in first line with chemotherapy in combination with an anti-EGFR drug, was assessed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
